Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Si Sun

Showing results (391-400 of 400) with videos related to

Pageof 40
Sort By:
You have reached the last page of results.This site can display upto 400 results.
Science Advances|November 10, 2021
An oligomeric semiconducting nanozyme with ultrafast electron transfers alleviates acute brain injuryXiaoyu Mu, Junying Wang, Hua He, et al.
Science Advances|August 2, 2023
Bioactive NIR-II gold clusters for three-dimensional imaging and acute inflammation inhibitionHuizhen Ma, Xiaoning Zhang, Ling Liu, et al.
Advanced Materials (Deerfield Beach, Fla.)|October 26, 2023
A Nanozyme-Based Electrode for High-Performance Neural RecordingShuangjie Liu, Yang Wang, Yue Zhao, et al.
Biomaterials|November 27, 2022
Respiratory mucosal vaccination of peptide-poloxamine-DNA nanoparticles provides complete protection against lethal SARS-CoV-2 challengeSi Sun, Entao Li, Gan Zhao, et al.
Nature Cancer|January 5, 2024
Author Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLCCaicun Zhou, Ziping Wang, Meili Sun, et al.
Journal of Translational Medicine|April 4, 2025
Impact of metagenomics next-generation sequencing on etiological diagnosis and early outcomes in sepsisFeixiang Xu, Chen Chen, Su Lu, et al.
Nature Cancer|June 15, 2023
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLCCaicun Zhou, Ziping Wang, Meili Sun, et al.
The Lancet. Respiratory Medicine|December 15, 2023
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trialMengzhao Wang, Yun Fan, Meili Sun, et al.
The Lancet. Oncology|June 16, 2025
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trialCaicun Zhou, Ziping Wang, Meili Sun, et al.
Cell Reports. Medicine|May 7, 2025
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutationYan Xu, James Chih-Hsin Yang, Yanqiu Zhao, et al.
Pageof 40

Showing results (391-400 of 400) with videos related to

Sort By:
Pageof 40
You have reached the last page of results.This site can display upto 400 results.
Science Advances|November 10, 2021
An oligomeric semiconducting nanozyme with ultrafast electron transfers alleviates acute brain injuryXiaoyu Mu, Junying Wang, Hua He, et al.
Science Advances|August 2, 2023
Bioactive NIR-II gold clusters for three-dimensional imaging and acute inflammation inhibitionHuizhen Ma, Xiaoning Zhang, Ling Liu, et al.
Advanced Materials (Deerfield Beach, Fla.)|October 26, 2023
A Nanozyme-Based Electrode for High-Performance Neural RecordingShuangjie Liu, Yang Wang, Yue Zhao, et al.
Biomaterials|November 27, 2022
Respiratory mucosal vaccination of peptide-poloxamine-DNA nanoparticles provides complete protection against lethal SARS-CoV-2 challengeSi Sun, Entao Li, Gan Zhao, et al.
Nature Cancer|January 5, 2024
Author Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLCCaicun Zhou, Ziping Wang, Meili Sun, et al.
Journal of Translational Medicine|April 4, 2025
Impact of metagenomics next-generation sequencing on etiological diagnosis and early outcomes in sepsisFeixiang Xu, Chen Chen, Su Lu, et al.
Nature Cancer|June 15, 2023
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLCCaicun Zhou, Ziping Wang, Meili Sun, et al.
The Lancet. Respiratory Medicine|December 15, 2023
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trialMengzhao Wang, Yun Fan, Meili Sun, et al.
The Lancet. Oncology|June 16, 2025
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trialCaicun Zhou, Ziping Wang, Meili Sun, et al.
Cell Reports. Medicine|May 7, 2025
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutationYan Xu, James Chih-Hsin Yang, Yanqiu Zhao, et al.
Pageof 40